Shenzhen Neptunus Bioengineering Co (000078) Fair Value & Analysis

Healthcare · CN · Market cap 4.2B CNY

Below-average quality, and screening another 45% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (¥1.37). The favourable scenario is already priced in.
• Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.

How to read this chart

60‑month range ¥1.29 – ¥5.29 · fair‑value band ¥0.9500 – ¥1.37 · the ¥1.74 price screens above the ¥0.9500 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 21, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Shenzhen Neptunus Bioengineering Co (000078) currently trades at ¥1.74, while our model-based Fair Value estimate is ¥0.9500, implying the stock looks roughly 45.4% overvalued today. The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, Shenzhen Neptunus Bioengineering Co generated revenue of 25.2B CNY at a net margin of -2.3%. Revenue declined 19.4% year over year. It earns a return on equity of -22.8%. Net debt stands at 8.5B CNY. Fundamentals as of Jul 21, 2026

Our scenario range runs from ¥0.9500 (bear case) to ¥1.37 (bull case); at ¥1.74, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 69% below its 52-week high and 18% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -45%, 000078 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Multiples (¥4.67) versus Asset-Based (¥0.3100). Highest evidence: ROIC Compounder (72).

Key figures & financial health

Quality Score breakdown

About the company

Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, production, and sale of Chinese patent medicines, infusion products, and western medicine preparations in China.

Full company description

Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, production, and sale of Chinese patent medicines, infusion products, and western medicine preparations in China. The company provides oryzanol tablets, chlorpheniramine maleate tablets, estazolam tablets, and rifampicin capsules, as well as technical support for generic drug quality consistency evaluation and other medical research and development work. It also distributes drugs, medical devices, and other medical supplies; and offers value-added services for hospitals, medical institutions, and drug retail institutions and distributors. In addition, the company provides drugs in the fields of malignant tumors, cardiovascular and cerebrovascular diseases, neurodegenerative diseases, diabetes, infectious diseases, and multiple diseases, such as respiratory system and digestive system. It develops HW130 injection that completed the Phase I clinical trial for anti-tumor; and NEP018 for anti-tumor. Shenzhen Neptunus Bioengineering Co., Ltd. was founded in 1992 and is headquartered in Shenzhen, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Shenzhen Neptunus Bioengineering Co reported revenue of ¥26.7B in FY2025 versus ¥41.1B in FY2021, a compound −10.2%/yr. Reported net income was −¥563M in FY2025.

000078 screens 45% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →

Peer Group

Drug Manufacturers - Specialty & Generic · 626 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.